{"id":"hr-1703","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5432020","moleculeType":null,"molecularWeight":"1336.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HR-1703 is a small-molecule kinase inhibitor developed by Guangdong Hengrui Pharmaceutical. While the precise molecular targets have not been widely disclosed in public literature, it is being evaluated in phase 3 clinical trials for cancer indications. The drug likely works by inhibiting one or more receptor tyrosine kinases or intracellular signaling proteins critical to tumor survival.","oneSentence":"HR-1703 is a tyrosine kinase inhibitor that targets specific oncogenic pathways to inhibit tumor cell growth and proliferation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:36.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication under phase 3 evaluation not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT06653322","phase":"PHASE3","title":"A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2024-11-21","conditions":"Asthma With Eosinophilic Phenotype","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HR-1703","genericName":"HR-1703","companyName":"Guangdong Hengrui Pharmaceutical Co., Ltd","companyId":"guangdong-hengrui-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HR-1703 is a tyrosine kinase inhibitor that targets specific oncogenic pathways to inhibit tumor cell growth and proliferation. Used for Cancer (specific indication under phase 3 evaluation not publicly detailed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}